Mission Statement, Vision, & Core Values (2026) of Northeast Pharmaceutical Group Co., Ltd.

Founded in 1993, Northeast Pharmaceutical Group Co., Ltd. has grown into a top-five Chinese pharmaceutical leader with a portfolio of more than 400 medication varieties and a 2024 sales revenue of approximately RMB 18 billion, delivering a net profit of RMB 2.5 billion (a 14% year‑over‑year increase) driven by surging cardiovascular (+25%) and export (+30%) sales; the company reinforced its innovation-first mission with RMB 1.2 billion invested in R&D in 2024 (building on ~$200 million in 2023, ~15% of revenue), targeted targets to allocate 15% of annual revenue to R&D by 2025, pursue AI‑enabled drug discovery to cut development timelines 30% by mid‑2024, advance over 50 new drug candidates by 2025, expand sales into 30+ countries aiming for 40% international revenue, reduce generic drug costs by 20% within three years, and uphold core values that produced a 20% drop in regulatory violations, a 99% quality‑audit compliance rate, three new compounds from a $150 million 2024 investment, partnerships with 20+ international research institutions, and social programs delivering over 500,000 free vaccinations supported by a $2 million budget while maintaining an 85% customer satisfaction rate in 2023.

Northeast Pharmaceutical Group Co., Ltd. (000597.SZ) - Intro

• Founded: 1993
• Product portfolio: >400 varieties
• Key therapeutic areas: Anti-infectives, Cardiovascular, Endocrine
• Market position (2024): Top five pharmaceutical firms in China

Mission

• Deliver safe, accessible and innovative medicines that improve patient outcomes.
• Integrate scientific excellence with scalable manufacturing to meet public health needs.
• Drive sustainable growth for stakeholders while upholding regulatory and ethical standards.

Vision

• To be a globally respected Chinese pharmaceutical innovator recognized for breakthrough therapies and reliable supply chains.
• Expand international reach with quality exports and collaborative R&D partnerships.

Core Values

• Patient-first: prioritize efficacy, safety and accessibility of medicines.
• Innovation: sustained investment in R&D to discover and develop new therapies.
• Quality & Compliance: rigorous manufacturing standards and regulatory adherence.
• Collaboration: build partnerships across academia, industry and government.
• Sustainability: responsible growth balancing social impact and shareholder value.

2024 Key Financial & Operational Highlights

Strategic Priorities Aligned with Mission & Vision

• Accelerate pipeline advancement by allocating >RMB 1 billion annually to clinical development and biologics platforms.
• Scale export channels to sustain the reported 30% growth and target new markets in Southeast Asia, Africa and Latin America.
• Strengthen cardiovascular franchise given the 25% sales uplift; prioritize lifecycle management and new delivery systems.
• Enhance manufacturing capacity and quality systems to support domestic leadership and global regulatory approvals.

Northeast Pharmaceutical Group Co., Ltd. (000597.SZ) - Overview

• Mission Statement: Deliver safe, effective medicines through rigorous quality control, continuous R&D investment, and patient-centered access initiatives.
• Vision: Be a leading, innovation-driven pharmaceutical provider that expands global patient access to essential therapies.
• Core Values: Quality, Integrity, Innovation, Collaboration, Patient Focus.

• Stringent quality control across production lines to ensure product efficacy and safety, aligned with national and international GMP standards.
• Continuous monitoring and batch-level testing to maintain patient trust and regulatory compliance.

• R&D investment reached approximately $200 million in 2023, representing roughly 15% of total revenue, signaling a sustained commitment to pipeline growth and therapeutic innovation.
• Strategic partnerships and investments in advanced technologies (e.g., biologics development platforms, process intensification) to accelerate new treatments and improve existing therapies.

• Customer-centric engagement with healthcare providers and patients produced an 85% customer satisfaction rate in 2023.
• Committed targets to improve access - aiming to reduce the cost of generic medications by 20% within the next three years to lower patient financial burden.

• Maintain and enhance manufacturing quality systems to safeguard product safety and efficacy.
• Scale R&D efforts to sustain a robust development pipeline and transition promising candidates toward clinical milestones.
• Leverage partnerships (industrial, academic, and technology) to shorten development timelines and broaden therapeutic scope.
• Implement pricing and distribution strategies to meet the 20% generic cost-reduction goal while preserving commercial sustainability.

Northeast Pharmaceutical Group Co., Ltd. (000597.SZ) - Mission Statement

• Allocate 15% of annual revenue to research & development by 2025 to accelerate pipeline growth and clinical advancement.
• Expand global footprint to sales in 30+ emerging and developed markets by 2025, with international revenue contributing 40% of total sales.
• Reduce corporate carbon footprint by 25% by 2025; achieved a 10% emissions reduction year-over-year to date.
• Lower the cost of essential generic medications by 20% over the next three years to enhance patient access.
• Integrate artificial intelligence into drug discovery workflows to shorten development timelines by 30% (target mid-2024 for initial impact).
• Advance development of over 50 new drug candidates across discovery, preclinical, and clinical stages by 2025.

• Core Values:
  • Patient-Centricity - prioritize access, affordability, and quality.
  • Innovation - sustained R&D and AI adoption to drive novel therapies.
  • Integrity - compliance, transparent reporting, and ethical supply chains.
  • Sustainability - measurable reductions in emissions and resource use.
  • Global Partnership - collaborate with international stakeholders to widen reach.
• Strategic Initiatives:
  • Increase R&D budget allocation and form biotech collaborations to populate a 50+ candidate pipeline.
  • Deploy AI platforms in cheminformatics and lead optimization to meet the 30% timeline reduction target.
  • Scale manufacturing efficiencies and generic portfolio optimization to achieve a 20% price reduction for essential generics.
  • Execute targeted market-entry strategies in emerging markets to reach 30+ countries and 40% international revenue.
  • Implement energy-efficiency retrofits and renewable sourcing to drive the 25% carbon reduction goal.

Northeast Pharmaceutical Group Co., Ltd. (000597.SZ) - Vision Statement

• Mission focus: advance human health through research-driven drug development, accessible care initiatives, and sustainable operations.
• Strategic horizon: expand global reach via partnerships, targeted R&D investments, and continuous quality elevation.
• Stakeholder promise: create long-term value for patients, healthcare providers, employees, shareholders, and communities.

• Integrity - foundational to all operations. A new compliance program implemented in 2024 produced a 20% reduction in regulatory violations year-over-year (from 50 violations in 2023 to 40 in 2024), reinforcing transparent governance and risk controls.
• Innovation - drives R&D. The company invested $150 million in 2024, resulting in the launch of three new drug compounds targeting chronic diseases (cardio-metabolic, autoimmune, and chronic respiratory indications).
• Quality assurance - a non-negotiable priority. External regulator quality audits in 2024 recorded a 99% compliance rate, supported by strengthened QA/QC labs and process controls.
• Social responsibility - tangible community impact. Over 500,000 free vaccinations were administered to underserved communities in 2024 under programs funded with a $2 million budget.
• Collaboration - accelerates capability. Partnerships with more than 20 international research institutions in 2024 expanded access to novel platforms, licensing opportunities, and shared clinical programs.
• Customer delight - commitment to patient and customer needs by delivering high-quality products at competitive prices and responsive service models.

• Strengthen compliance and ethics training, expanding the 2024 program to cover all subsidiaries and sales channels.
• Scale R&D pipelines: allocate multi-year funding to progress the three 2024-launched compounds into late-stage clinical development.
• Maintain and improve QA metrics to preserve the 99% external audit compliance baseline and reduce product recalls to <0.5% of batches.
• Expand community health programs, targeting 1 million vaccinations by 2026 through partnerships and targeted funding.
• Deepen international collaborations to co-develop biologics, precision-medicine diagnostics, and licensing deals.
• Enhance customer-facing platforms to monitor satisfaction, pricing competitiveness, and product availability in key markets.